Sequential combined therapy with thaiidomide and narrow-band (tl01) uvb in the treatment of prurigo nodularis

C. Ferrándiz; J. M. Carrascosa; M. Just; I. Bielsa; M. Ribera

doi:10.1159/000245988

Sequential combined therapy with thaiidomide and narrow-band (tl01) uvb in the treatment of prurigo nodularis

C. Ferrándiz, J. M. Carrascosa, M. Just, I. Bielsa, M. Ribera

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

49 Citations (Scopus)

Abstract

Background: Prurigo nodularis (PN) is a chronic disease of which treatment choices are limited. Among them, thaiidomide and phototherapy have been used with satisfactory results. Unfortunately, the possibility of side effects limits their use. Objective: To evaluate the efficacy of a sequential combined treatment with thaiidomide and ultraviolet B (UVB) therapy in order to minimize side effects and, thus, making possible a long-term treatment. Methods: A prospective open trial combining thaiidomide as initial therapy followed by narrow-band UVB (TL01) irradiation until complete or almost complete remission of the disease was achieved. Results: An excellent response was obtained after an average of 12 weeks of thaiidomide therapy and 32 UVB courses. Conclusions: Sequential combined therapy with thaiidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age. © 1997 S. Karger AG, Basel.

Original language	English
Pages (from-to)	359-361
Journal	Dermatology
Volume	195
Issue number	4
DOIs	https://doi.org/10.1159/000245988
Publication status	Published - 1 Jan 1997

Keywords

Prurigo nodularis
Thalidomide
Ultraviolet B

Access to Document

10.1159/000245988

Fingerprint Dive into the research topics of 'Sequential combined therapy with thaiidomide and narrow-band (tl01) uvb in the treatment of prurigo nodularis'. Together they form a unique fingerprint.

Cite this

@article{5763828bcf56476b86c6bb389b08ab9f,

title = "Sequential combined therapy with thaiidomide and narrow-band (tl01) uvb in the treatment of prurigo nodularis",

abstract = "Background: Prurigo nodularis (PN) is a chronic disease of which treatment choices are limited. Among them, thaiidomide and phototherapy have been used with satisfactory results. Unfortunately, the possibility of side effects limits their use. Objective: To evaluate the efficacy of a sequential combined treatment with thaiidomide and ultraviolet B (UVB) therapy in order to minimize side effects and, thus, making possible a long-term treatment. Methods: A prospective open trial combining thaiidomide as initial therapy followed by narrow-band UVB (TL01) irradiation until complete or almost complete remission of the disease was achieved. Results: An excellent response was obtained after an average of 12 weeks of thaiidomide therapy and 32 UVB courses. Conclusions: Sequential combined therapy with thaiidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age. {\textcopyright} 1997 S. Karger AG, Basel.",

keywords = "Prurigo nodularis, Thalidomide, Ultraviolet B",

author = "C. Ferr{\'a}ndiz and Carrascosa, {J. M.} and M. Just and I. Bielsa and M. Ribera",

year = "1997",

month = jan,

day = "1",

doi = "10.1159/000245988",

language = "English",

volume = "195",

pages = "359--361",

journal = "Dermatology",

issn = "1018-8665",

number = "4",

}

TY - JOUR

T1 - Sequential combined therapy with thaiidomide and narrow-band (tl01) uvb in the treatment of prurigo nodularis

AU - Ferrándiz, C.

AU - Carrascosa, J. M.

AU - Just, M.

AU - Bielsa, I.

AU - Ribera, M.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Background: Prurigo nodularis (PN) is a chronic disease of which treatment choices are limited. Among them, thaiidomide and phototherapy have been used with satisfactory results. Unfortunately, the possibility of side effects limits their use. Objective: To evaluate the efficacy of a sequential combined treatment with thaiidomide and ultraviolet B (UVB) therapy in order to minimize side effects and, thus, making possible a long-term treatment. Methods: A prospective open trial combining thaiidomide as initial therapy followed by narrow-band UVB (TL01) irradiation until complete or almost complete remission of the disease was achieved. Results: An excellent response was obtained after an average of 12 weeks of thaiidomide therapy and 32 UVB courses. Conclusions: Sequential combined therapy with thaiidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age. © 1997 S. Karger AG, Basel.

AB - Background: Prurigo nodularis (PN) is a chronic disease of which treatment choices are limited. Among them, thaiidomide and phototherapy have been used with satisfactory results. Unfortunately, the possibility of side effects limits their use. Objective: To evaluate the efficacy of a sequential combined treatment with thaiidomide and ultraviolet B (UVB) therapy in order to minimize side effects and, thus, making possible a long-term treatment. Methods: A prospective open trial combining thaiidomide as initial therapy followed by narrow-band UVB (TL01) irradiation until complete or almost complete remission of the disease was achieved. Results: An excellent response was obtained after an average of 12 weeks of thaiidomide therapy and 32 UVB courses. Conclusions: Sequential combined therapy with thaiidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age. © 1997 S. Karger AG, Basel.

KW - Prurigo nodularis

KW - Thalidomide

KW - Ultraviolet B

U2 - 10.1159/000245988

DO - 10.1159/000245988

M3 - Article

VL - 195

SP - 359

EP - 361

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 4

ER -